UNRESECTABLE MALIGNANT SOLID NEOPLASM
Clinical trials for UNRESECTABLE MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for UNRESECTABLE MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat cancers with gene mutations
Disease control OngoingThis study tests a combination of three drugs (copanlisib, nivolumab, and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to see if adding copanlisib to standard immunotherapy works better at controlling tumor growth.…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New combo targets Cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs (avelumab and M6620) in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see how well the drugs work together t…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific genetic changes. The goal was to find the best dose and check for side effects, while seeing if the combination could shrink or s…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
Experimental combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tests two oral drugs, ZEN003694 and binimetinib, together in people with advanced solid tumors that have RAS gene changes or triple-negative breast cancer. The goal is to find the safest dose and understand side effects. About 42 adults whose cancer has spr…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a combination of two drugs, trametinib and navitoclax, in people with advanced solid tumors that have specific mutations in the KRAS or NRAS genes. The goal is to find the safest dose and see if the drugs can shrink tumors or slow their growth. About 96 participa…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
New drug cocktail aims to starve and block cancer growth
Disease control OngoingThis early-phase trial tested a combination of two drugs (cediranib and selumetinib) in 19 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see how well the drugs worked together. Cediranib cuts off blo…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
Triple threat against tough cancers: drug combo plus radiation shows promise
Disease control OngoingThis study tests a new combination of two drugs (peposertib and avelumab) plus a special type of radiation for people with advanced solid tumors or bile duct cancers that have spread. The goal is to find the safest dose and see if the treatment can shrink tumors. About 103 adults…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising combo targets Hard-to-Treat HER2 cancers
Disease control TerminatedThis early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together for people with advanced solid tumors that have HER2 gene changes. The study includes up to 33 adults whose cancer has spread or cannot be removed by surgery. Th…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThis early-phase study tests the safety of adding the drug atezolizumab after a patient's own immune cells have been collected, multiplied, and infused back to fight cancer. It includes 40 adults with advanced blood or solid tumors that no longer respond to standard treatments. T…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Drug duo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs—pembrolizumab and interleukin-12—in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest and most effective dose, and to see if the combo can help the immune s…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug targets Cancer's fuel source in Gene-Mutated tumors
Disease control OngoingThis study tests a drug called telaglenastat (CB-839) that blocks an enzyme tumors need to grow. It is for people with advanced solid tumors or malignant peripheral nerve sheath tumors that have certain gene mutations (NF1, KEAP1/NRF2, or LKB1). The goal is to see if stopping the…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New combo targets Hard-to-Treat cancers with gene mutations
Disease control TerminatedThis study tests whether adding a targeted drug (ipatasertib) to standard chemotherapy (paclitaxel) can shrink or slow advanced solid tumors that have PTEN or AKT gene changes. About 33 adults whose cancer did not respond to taxane chemotherapy will receive the combination. The g…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called copanlisib combined with immunotherapy drugs (nivolumab, with or without ipilimumab) in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The goal is to find a dose t…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs (copanlisib, olaparib, and durvalumab) in 39 adults with advanced solid tumors that have spread or cannot be removed. The goal is to find the safest dose and see how well the drugs work together. Participants must have spe…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New immune cell therapy targets five Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Scientists peek inside tumors to see how new drug fights HER2 cancers
Knowledge-focused OngoingThis early-phase study looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. Researchers will take small tumor samples before and after treatment to measure chang…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC